$INTI
Inhibitor Therapeutics, Inc.

2019 Q4 Form 10-Q Financial Statement

#000119312519287359 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $294.6K $318.5K $400.1K
YoY Change -56.3% -20.4% 60.03%
% of Gross Profit
Research & Development $343.3K $364.4K $775.4K
YoY Change -47.62% -53.0% 78.86%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $637.9K $682.9K $1.176M
YoY Change -52.02% -41.91% 72.58%
Operating Profit -$682.9K -$1.176M
YoY Change -41.91% 72.58%
Interest Expense $2.050K $4.370K $4.000K
YoY Change -38.25% 9.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$635.8K -$678.6K -$1.172M
YoY Change -52.06% -42.08% 72.28%
Income Tax
% Of Pretax Income
Net Earnings -$635.8K -$678.5K -$1.172M
YoY Change -52.06% -42.08% 72.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.716K -$1.832K -$3.167K
COMMON SHARES
Basic Shares Outstanding 370.4M 370.4M 370.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $803.8K $1.372M $1.441M
YoY Change -27.5% -4.76% 61.89%
Cash & Equivalents $803.8K $1.372M $1.441M
Short-Term Investments
Other Short-Term Assets $42.45K $50.66K $51.44K
YoY Change 2.78% -1.52% -82.85%
Inventory
Prepaid Expenses $42.45K $50.66K $51.44K
Receivables
Other Receivables
Total Short-Term Assets $846.3K $1.423M $1.742M
YoY Change -26.41% -18.33% 46.49%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.70K $61.02K $90.32K
YoY Change -35.29% -32.43% -24.49%
Total Long-Term Assets $53.70K $61.02K $90.32K
YoY Change -35.29% -32.43% -24.49%
TOTAL ASSETS
Total Short-Term Assets $846.3K $1.423M $1.742M
Total Long-Term Assets $53.70K $61.02K $90.32K
Total Assets $900.0K $1.484M $1.833M
YoY Change -27.01% -19.03% 40.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $315.9K $286.0K $328.0K
YoY Change -17.9% -12.81% 50.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $431.1K $358.9K $549.1K
YoY Change -38.47% -34.63% 117.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $0.00
YoY Change 500.0%
Total Long-Term Liabilities $3.000M $3.000M $0.00
YoY Change 500.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $431.1K $358.9K $549.1K
Total Long-Term Liabilities $3.000M $3.000M $0.00
Total Liabilities $3.431M $3.359M $549.1K
YoY Change 185.77% 511.74% 117.71%
SHAREHOLDERS EQUITY
Retained Earnings -$55.91M -$55.23M -$51.60M
YoY Change 5.54% 7.02% 8.94%
Common Stock $49.42M $49.39M $48.93M
YoY Change 0.75% 0.95% 1.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.531M -$1.875M -$2.677M
YoY Change
Total Liabilities & Shareholders Equity $900.0K $1.484M $1.833M
YoY Change -27.01% -19.03% 40.01%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$635.8K -$678.5K -$1.172M
YoY Change -52.06% -42.08% 72.52%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$568.4K -$553.8K -$956.2K
YoY Change -31.7% -42.08% 25.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -99.18K 1.603M
YoY Change -100.0% -106.19%
NET CHANGE
Cash From Operating Activities -568.4K -553.8K -956.2K
Cash From Investing Activities
Cash From Financing Activities 0.000 -99.18K 1.603M
Net Change In Cash -568.4K -653.0K 646.7K
YoY Change 71.13% -200.97% -185.09%
FREE CASH FLOW
Cash From Operating Activities -$568.4K -$553.8K -$956.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61023
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82992
CY2019Q3 us-gaap Assets
Assets
1483869
CY2018Q4 us-gaap Assets
Assets
1233001
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1372186
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2019Q3 us-gaap Assets Current
AssetsCurrent
1422846
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1150009
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Liabilities
Liabilities
3358925
CY2018Q4 us-gaap Liabilities
Liabilities
1200650
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
50660
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41296
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
285982
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
384829
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49354791
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49015120
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
37045
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37008
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1483869
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1233001
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
358925
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
700650
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22533
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
215876
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55227758
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52980643
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-1875056
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-682921
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1175525
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
364442
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
775449
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
318479
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
400076
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4373
CY2018Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3995
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-678548
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1171530
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369930943
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
864812
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1978294
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1245209
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1256453
us-gaap Operating Income Loss
OperatingIncomeLoss
-2110021
us-gaap Operating Income Loss
OperatingIncomeLoss
-3234747
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12494
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10707
us-gaap Net Income Loss
NetIncomeLoss
-2097527
us-gaap Net Income Loss
NetIncomeLoss
-3224040
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370427615
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369757743
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
682921
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
1175525
us-gaap Operating Expenses
OperatingExpenses
2110021
us-gaap Operating Expenses
OperatingExpenses
3234747
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2018Q2 hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
12000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370084064
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370084064
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-881916
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
125451
CY2019Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
50410
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
99945
CY2019Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
500000
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
131031
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
81614
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-632691
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1173215
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
27117
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
208243
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1170594
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
83953
CY2019Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
50410
CY2019Q3 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-728958
CY2018Q3 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1221064
CY2018Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49534
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
149588
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2247115
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3330122
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
106082
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-822418
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-1638299
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-2677364
us-gaap Profit Loss
ProfitLoss
-2097527
us-gaap Profit Loss
ProfitLoss
-3224040
us-gaap Share Based Compensation
ShareBasedCompensation
239762
us-gaap Share Based Compensation
ShareBasedCompensation
417647
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12605
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-32183
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-292189
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-101943
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2137349
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2876153
hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
3960866
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
263473
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1096713
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1440826
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1000000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2019Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2019Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
50410
CY2018Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
26630
CY2018Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
29918
CY2018Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49534
hppi Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
2500000
us-gaap Stock Issued1
StockIssued1
99946
hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
50410
hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49534
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2400822
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3972866
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
500000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
56548
us-gaap Stock Issued1
StockIssued1
56548
us-gaap Payments Of Dividends
PaymentsOfDividends
99178
hppi Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
hppi Description Of Royalty Payment
DescriptionOfRoyaltyPayment
With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370446185
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
hppi Fair Value Inputs Royalty Rate
FairValueInputsRoyaltyRate
0.70
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001193125-19-287359-index-headers.html Edgar Link pending
0001193125-19-287359-index.html Edgar Link pending
0001193125-19-287359.txt Edgar Link pending
0001193125-19-287359-xbrl.zip Edgar Link pending
d787025d10q.htm Edgar Link pending
d787025dex101.htm Edgar Link pending
d787025dex311.htm Edgar Link pending
d787025dex312.htm Edgar Link pending
d787025dex321.htm Edgar Link pending
d787025dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20190930.xml Edgar Link completed
hppi-20190930.xsd Edgar Link pending
hppi-20190930_cal.xml Edgar Link unprocessable
hppi-20190930_def.xml Edgar Link unprocessable
hppi-20190930_lab.xml Edgar Link unprocessable
hppi-20190930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending